How to Taper Off GLP-1: A Step-by-Step Protocol

If you've decided to stop your GLP-1 medication, the question is not just whether to stop, but how. The rebound rates in trials are calculated from patients who stopped abruptly. A deliberate taper produces meaningfully better outcomes for most patients.

Why taper instead of cold turkey

Three reasons:

Appetite returns gradually. A taper allows you to practice managing each level of returning hunger before it gets stronger.
Habits consolidate. Each step gives you weeks at a new level to confirm your protein, lifting, and routine hold.
You can detect early drift. A rebound on a step-down is a signal to hold or restart, not a full year of regain.

The general taper protocol

Talk to your prescriber for your specific situation, but the typical approach:

Phase 1 (months 1–2 off-ramp): Step down to the next-lower dose level. Maintain for 8–12 weeks. Confirm:

Weight is stable or still slowly decreasing
Protein intake hasn't dropped
Lifting routine hasn't slipped
You can hit your eating windows without distress

Phase 2 (months 3–4): Step down to the next dose. Same 8–12 weeks. Same checks. Hunger is more present now; this is the stretch where most habit slippage happens.

Phase 3 (months 5–6): Either step down to the lowest dose available, OR maintain the prior step but stretch the dosing interval (e.g., every 10 days instead of weekly).

Phase 4 (months 7+): If you've been stable through Phase 3, consider:

Stopping entirely
Maintaining at the lowest dose long-term
Maintaining at extended intervals (every 2 weeks)

Specific drug examples

Semaglutide (Ozempic, Wegovy)

Standard down-step pattern:

2.4 mg → 1.7 mg (8–12 weeks)
1.7 mg → 1.0 mg (8–12 weeks)
1.0 mg → 0.5 mg (8–12 weeks)
0.5 mg → 0.25 mg (8 weeks)
0.25 mg → stop, OR every 2 weeks at 0.25 mg, OR maintain

Tirzepatide (Mounjaro, Zepbound)

15 mg → 12.5 mg (8 weeks)
12.5 mg → 10 mg (8 weeks)
10 mg → 7.5 mg (8–12 weeks)
7.5 mg → 5 mg (8–12 weeks)
5 mg → 2.5 mg (8 weeks)
2.5 mg → stop, OR every 2 weeks, OR maintain

Liraglutide (Saxenda)

3.0 mg → 2.4 mg (4 weeks)
2.4 mg → 1.8 mg (4 weeks)
1.8 mg → 1.2 mg (4 weeks)
1.2 mg → stop

(Liraglutide is daily and shorter-acting, so the taper can be quicker, but the principle is the same.)

What to monitor during the taper

Weekly weigh-in. Same day, same time, same conditions. Track the trend, not the daily noise.

Weekly protein audit. Are you still hitting your floor? If not, add a shake.

Weekly training log. Sessions completed? Weights moving up?

Sleep quality. Some patients sleep better as GLP-1 dose decreases (less GI discomfort); some sleep worse (more food noise at night). Track.

Appetite patterns. Where is hunger showing up that wasn't there before? Plan for it.

Mood and energy. Some patients experience low-mood symptoms in the first weeks of each step-down. Usually resolves.

What to do if regain starts during taper

A 2–4 lb gain over a step-down is normal and not a stop signal — water and glycogen redistribute as appetite normalizes.

A 5+ lb gain over a single step, or a clear 1+ lb/week trend, is signal:

Option A: Hold at the current dose for an additional 8–12 weeks. Reinforce habits. See if weight stabilizes.

Option B: Step back up to the previous dose. Stay there for 8–12 weeks. Try the step-down again.

Option C: Accept that you may be a long-term maintenance patient. Many are.

There is no failure here. The medication is doing what it does. The decision tree is about practical management.

What to do after fully stopping

Months 1–2 off: Hunger ramps. Habits matter. Daily structure matters.

Months 3–6 off: This is when most rebound shows up. Weekly weigh-ins. Honest food audits if drift starts.

Months 6–12 off: New equilibrium. If you're stable here, you have a real shot at long-term maintenance.

Year 2+: The further you go, the better the prognosis — but rebound can still happen if habits collapse.

Restart criteria

If you stopped fully and want to restart, the medical conversation usually looks at:

Sustained 5%+ regain over months
Active deterioration of metabolic markers
Loss of function or quality of life
Strong patient preference

Restarting at a low maintenance dose is increasingly common and considered medically reasonable. The framing of GLP-1 as a chronic-disease medication (like blood pressure meds) supports this.

Long-term maintenance dose

For patients who decide to stay on indefinitely:

Semaglutide 0.25–0.5 mg/week is enough for many to maintain
Tirzepatide 2.5–5 mg/week is enough for many
Every-other-week dosing is an option some prescribers use
The cost is real but lower than the higher doses
The side effects are usually minimal at maintenance doses

This is a personal medical decision. There is no universal right answer.

Bottom line

Tapering off GLP-1 over 4–6 months meaningfully outperforms cold-turkey stopping for most patients. Step down every 8–12 weeks, monitor weight and habits, hold or restart if regain begins. Many patients should consider staying on a low maintenance dose long-term rather than stopping fully — the data supports treating these as chronic medications rather than temporary tools.